(Q37588717)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

review article

1 reference

title

Emerging Raf inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Paolo Lunghi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Massimo Libra

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Giuseppe Montalto

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Ferdinando Nicoletti

12

1 reference

ORCID Public Data File 2021

Linda S Steelman

2

object named as

Linda S Steelman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

14

Alberto M Martelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

4

William H Chappell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

11

Franca Stivala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

7

Michele Milella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

8

Agostino Tafuri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

10

Antonio Bonati

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

16

Melchiorre Cervello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Steven L Abrams

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Suzanne Russo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Roger Ove

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

633-648

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

MAP kinase pathways: the first twenty years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Back to the roots: the remarkable RAF oncogene story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Signaling through RAS-RAF-MEK-ERK: from basics to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Ras oncogenes and their downstream targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Regulation of Raf-1 by direct feedback phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Bcl2's flexible loop domain regulates p53 binding and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Activation of the MAPK module from different spatial locations generates distinct system outputs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

The genome and epigenome of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

BRAF signaling and targeted therapies in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Extracellular HSP90: conquering the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Equitable Allocation of Antiretrovirals in Resource-Constrained Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Selective Raf inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Obesity and diabetes as a risk factor for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Obesity and cancer risk: a Danish record-linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903232633

10.1517/14728210903232633

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19715444%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference